{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:21:06Z","timestamp":1791105666081,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1016\/j.parkreldis.2005.05.008","type":"journal-article","created":{"date-parts":[[2005,9,10]],"date-time":"2005-09-10T12:17:54Z","timestamp":1126354674000},"page":"449-452","source":"Crossref","is-referenced-by-count":68,"title":["Amantadine reduces the duration of levodopa-induced dyskinesia: A randomized, double-blind, placebo-controlled study"],"prefix":"10.1016","volume":"11","author":[{"given":"Francisco","family":"Pereira da Silva-J\u00fanior","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Braga-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisca","family":"Sueli Monte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veralice","family":"Meireles Sales de Bruin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 3","key":"10.1016\/j.parkreldis.2005.05.008_bib1","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ana.10513","article-title":"Limitations of current Parkinson's disease therapy","volume":"53","author":"Rascol","year":"2003","journal-title":"Ann Neurol"},{"issue":"9","key":"10.1016\/j.parkreldis.2005.05.008_bib2","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/mds.20243","article-title":"Levodopa in the treatment of Parkinson's disease: current controversies","volume":"19","author":"Olanow","year":"2004","journal-title":"Mov Disord"},{"issue":"3","key":"10.1016\/j.parkreldis.2005.05.008_bib3","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/mds.1090","article-title":"Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature","volume":"16","author":"Ahlskog","year":"2001","journal-title":"Mov Disord"},{"issue":"2","key":"10.1016\/j.parkreldis.2005.05.008_bib4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/mds.10031","article-title":"Clinical-pathological study of levodopa complications","volume":"17","author":"Rajput","year":"2002","journal-title":"Mov Disord"},{"issue":"12","key":"10.1016\/j.parkreldis.2005.05.008_bib5","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s004150050530","article-title":"Risk factors for levodopa-induced dyskinesias in Parkinson's disease","volume":"246","author":"Grandas","year":"1999","journal-title":"J Neurol"},{"issue":"9","key":"10.1016\/j.parkreldis.2005.05.008_bib6","first-page":"889","article-title":"Pharmacological mechanisms of the treatment of dyskinesia in Parkinson's disease","volume":"28","author":"Jimenez-Jimenez","year":"1999","journal-title":"Rev Neurol"},{"issue":"6","key":"10.1016\/j.parkreldis.2005.05.008_bib7","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/00002826-200111000-00002","article-title":"Dyskinesias: l-dopa-induced and tardive dyskinesia","volume":"24","author":"Rascol","year":"2001","journal-title":"Clin Neuropharmacol"},{"issue":"suppl 1","key":"10.1016\/j.parkreldis.2005.05.008_bib8","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1212\/WNL.62.1_suppl_1.S17","article-title":"The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits","volume":"62","author":"Obeso","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2005.05.008_bib9","first-page":"497","article-title":"Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease","volume":"69","author":"Chase","year":"1996","journal-title":"Adv Neurol"},{"key":"10.1016\/j.parkreldis.2005.05.008_bib10","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1093\/brain\/awh290","article-title":"Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias","volume":"127","author":"De la Fuente-Fernandez","year":"2004","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.parkreldis.2005.05.008_bib11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1531-8257(200001)15:1<3::AID-MDS1003>3.0.CO;2-E","article-title":"Pathophysiology of motor response complications in Parkinson's disease: Hypotheses on the why, where and what","volume":"15","author":"Metman","year":"2001","journal-title":"Mov Disord"},{"issue":"suppl 1","key":"10.1016\/j.parkreldis.2005.05.008_bib12","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1212\/WNL.62.1_suppl_1.S47","article-title":"Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation","volume":"62","author":"Jenner","year":"2004","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.parkreldis.2005.05.008_bib13","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1008928321652","article-title":"Evaluation of a measurement strategy for Parkinson's disease: assessing patient health-related quality of life","volume":"9","author":"Damiano","year":"2000","journal-title":"Qual Life Res"},{"issue":"1","key":"10.1016\/j.parkreldis.2005.05.008_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1212\/WNL.58.1.11","article-title":"Practice parameter: initiation of treatment for Parkinson's disease: an evidence-based review: report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"58","author":"Miyasaki","year":"2002","journal-title":"Neurology"},{"issue":"Suppl. 5","key":"10.1016\/j.parkreldis.2005.05.008_bib15","first-page":"S165","article-title":"Depression in Parkinson's disease: own experience","volume":"37","author":"Golab","year":"2003","journal-title":"Neurol Neurochir Pol"},{"issue":"2","key":"10.1016\/j.parkreldis.2005.05.008_bib16","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/mds.20279","article-title":"Impact of motor complications of Parkinson's disease on the quality of life","volume":"20","author":"Chapuis","year":"2004","journal-title":"Mov Disord"},{"issue":"6979","key":"10.1016\/j.parkreldis.2005.05.008_bib17","first-page":"575","article-title":"Drug treatment of Parkinson's disease","volume":"310","author":"Quinn","year":"1995","journal-title":"Biol Med J"},{"issue":"1","key":"10.1016\/j.parkreldis.2005.05.008_bib18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0304-3940(02)01462-3","article-title":"Intravenous amantadine sulphate application improves the performance of complex but not simple motor tasks in patients with Parkinson's disease","volume":"339","author":"M\u00fcller","year":"2003","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.parkreldis.2005.05.008_bib19","doi-asserted-by":"crossref","unstructured":"Crosby NJ, Deane KHO, Clarke CE. Amantadine for dyskinesia in Parkinson's disease (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 2003.","DOI":"10.1002\/14651858.CD003467"},{"key":"10.1016\/j.parkreldis.2005.05.008_bib20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J Psychiatry Res"},{"issue":"3","key":"10.1016\/j.parkreldis.2005.05.008_bib21","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/1531-8257(199905)14:3<448::AID-MDS1010>3.0.CO;2-0","article-title":"Clinical rating of dyskinesias in Parkinson's disease: use and reliability of a new rating scale","volume":"14","author":"Hagell","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.parkreldis.2005.05.008_bib22","unstructured":"Norusis M.J. SPSS for Windows: Base System User's Guide, release 6.0; 1993."},{"issue":"2","key":"10.1016\/j.parkreldis.2005.05.008_bib23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00002826-200003000-00004","article-title":"The effect of amantadine on levodopa-induced dyskinesias in Parkinson's disease: a double-blind, placebo-controlled study","volume":"23","author":"Snow","year":"2000","journal-title":"Clin Neuropharmacol"},{"issue":"5","key":"10.1016\/j.parkreldis.2005.05.008_bib24","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I","article-title":"Beneficial effects of amantadine on l-dopa-induced dyskinesias in Parkinson's disease","volume":"15","author":"Luginger","year":"2000","journal-title":"Mov Disord"},{"issue":"5","key":"10.1016\/j.parkreldis.2005.05.008_bib25","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1212\/WNL.50.5.1323","article-title":"Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease","volume":"50","author":"Metman","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2005.05.008_bib26","first-page":"141","article-title":"Duration of amantadine benefit on dyskinesia of severe Parkinson's disease","volume":"75","author":"Thomas","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"11","key":"10.1016\/j.parkreldis.2005.05.008_bib27","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.56.11.1383","article-title":"Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study","volume":"56","author":"Metman","year":"1999","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2005.05.008_bib28","doi-asserted-by":"crossref","unstructured":"Amantadine and other antiglutamate agents: management of Parkinson's disease. Mov Disord 2002;17(suppl 4):S13\u2013S22.","DOI":"10.1002\/mds.5557"},{"key":"10.1016\/j.parkreldis.2005.05.008_bib29","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/archneur.1991.00530210109030","article-title":"N-methyl-d-aspartate antagonists in the treatment of Parkinson's disease","volume":"48","author":"Greenamyre","year":"1991","journal-title":"Arch Neurol"},{"key":"10.1016\/j.parkreldis.2005.05.008_bib30","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/S0149-7634(96)00037-1","article-title":"Aminoadamantanes as NMDA receptor antagonists and antiparkinsonian agents-preclinical studies","volume":"21","author":"Danysz","year":"1997","journal-title":"Neurosci Biobehav Rev"},{"issue":"2","key":"10.1016\/j.parkreldis.2005.05.008_bib31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.nbd.2003.10.007","article-title":"Effect of a selective glutamate antagonist on l-dopa-induced dyskinesias in drug-naive parkinsonian monkeys","volume":"15","author":"Hadj Tahar","year":"2004","journal-title":"Neurobiol Dis"},{"issue":"23","key":"10.1016\/j.parkreldis.2005.05.008_bib32","first-page":"2003","article-title":"Memantine can relieve certain symptoms in Parkinson's disease. Improvement achieved in two out of three described cases with dyskinesia and cognitive failure","volume":"101","author":"Lokk","year":"2004","journal-title":"Lakartidningen"},{"issue":"1","key":"10.1016\/j.parkreldis.2005.05.008_bib33","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S0014-4886(03)00250-4","article-title":"A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease","volume":"184","author":"Bibbiani","year":"2003","journal-title":"Exp Neurol"},{"issue":"Suppl 6","key":"10.1016\/j.parkreldis.2005.05.008_bib34","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1212\/01.WNL.0000095209.59347.79","article-title":"A2A antagonists as novel non-dopaminergic therapy for motor dysfunction in PD","volume":"61","author":"Jenner","year":"2003","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.parkreldis.2005.05.008_bib35","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1212\/WNL.57.11.2078","article-title":"Prospective longitudinal assessment of hallucinations in Parkinson's disease","volume":"57","author":"Goetz","year":"2001","journal-title":"Neurology"}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802005000994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802005000994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T10:44:57Z","timestamp":1586429097000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802005000994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["S1353802005000994"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2005.05.008","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}